By Devika Patel
Knoxville, Tenn., June 18 - Accentia Biopharmaceuticals, Inc. revealed more details on an $8.8 million private placement of discounted secured convertible debentures, which settled on June 17, according to an 8-K filed Wednesday with the Securities and Exchange Commission.
The debentures, which mature June 17, 2011, are convertible into common stock at $1.10 per share.
After six months, the debentures will amortize through thirty equal installments.
The company may redeem the debentures at 110% of the outstanding principal.
The debentures were issued at an 8% original issue discount and bear interest at an annual rate of 8%, payable monthly starting one year from closing.
The offering includes warrants for 2,943,131 common shares, exercisable at $1.21 for six years.
Rodman & Renshaw, LLC is the agent.
Proceeds will be used to support development, regulatory and partnering strategies for SinuNase and Revimmune and support general operations.
Accentia is a biopharmaceutical company based in Tampa, Fla.
| Issuer: | Accentia Biopharmaceuticals, Inc.
|
| Issue: | Convertible debentures
|
| Amount: | $8,797,469
|
| Maturity: | June 17, 2011
|
| Coupon: | 8%
|
| Price: | 92
|
| Yield: | 8%
|
| Conversion price: | $1.10
|
| Redemption premium: | 110%
|
| Warrants: | For 2,943,131 shares
|
| Warrant expiration: | Six years
|
| Warrant strike price: | $1.21
|
| Agent: | Rodman & Renshaw, LLC
|
| Announcement date: | June 17
|
| Settlement date: | June 17
|
| Stock symbol: | Nasdaq: ABPI
|
| Stock price: | $1.28 at close June 16
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
